Renaissance Capital logo

Aligos Therapeutics Priced, Nasdaq: ALGS

Phase 1 biotech developing oligonucleotide therapies for viral and liver diseases.

Industry: Health Care

Latest Trade: $15.32 0.00 (0.0%)

First Day Return: -1.0%

Return from IPO: +2.1%

Industry: Health Care

We are a clinical-stage biopharmaceutical company currently focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases. We utilize our proprietary oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens designed to achieve improved treatment outcomes. Our lead effort is to develop a functional cure for Chronic Hepatitis B (CHB), which often results in other life-threatening conditions such as cirrhosis, end-stage liver disease (ESLD) and the most common form of liver cancer, hepatocellular carcinoma (HCC). The most widely used treatment for CHB, nucleos(t)ide analogs, suppresses viral replication but only achieves low rates of functional cure and often requires long-term administration. To address this issue, we have developed a portfolio of differentiated drug candidates for CHB, including an S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS) molecule, a small molecule Capsid Assembly Modulator (CAM), and oligonucleotides (ASO and siRNA), each of which is designed against clinically validated targets in the Hepatitis B Virus (HBV) life cycle. We believe that combination regimens utilizing our portfolio of CHB drug candidates may lead to higher rates of functional cure. A Phase 1 proof of concept trial for our STOPS molecule is ongoing in New Zealand and we expect to initiate a Phase 1 clinical trial with our CAM in the second half of 2020.
more less
IPO News for Aligos Therapeutics
more
IPO Data
IPO File Date 09/25/2020
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 10.0
Deal Size ($mm) $150
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 10/15/2020
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 10.0
Deal Size ($mm) $150
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters South San Francisco, CA
Founded 2018
Employees 67
Website www.aligos.com